Welcome! Here you can find resources for sites of care receiving and administering COVID-19 antibody infusions.
Important Update Regarding Bamlanivimab + Etesevimab Distribution
Important Notice: On June 25, 2021, the FDA is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice.
Important Notice: On April 16, 2021, the FDA revoked emergency use authorization for bamlanivimab monotherapy due to the increased prevalence of SARS-CoV-2 variants that are expected to be resistant to bamlanivimab administered alone. This change comes at the request of the manufacturer, Eli Lilly, due to the availability of more efficacious monoclonal antibody therapies, and is not related to any adverse events or safety issues. For more information, see the FDA’s Letter of Revocation, and Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Bamlanivimab Administered Alone.
Virtual Event Opportunity with Medscape
Want to learn about neutralizing monoclonal antibodies in COVID-19 and infusion center operations? Click the button below to see any open slots available for a virtual event opportunity to get answers to your most pressing questions.
Casirivimab and Imdevimab are supplied in multiple packaging configurations and have unique preparation requirements that may increase risk for medication errors.
Use this flowsheet to document infusion therapies and provide a detailed record to fax to the referring prescriber. The flowsheet also guides the clinician to adhere to administration and documentation requirements. (Updated 6-15-21)
Review these notes on medication stability and storage to ensure product and patient safety. (Updated 6-15-2021)
Regeneron Casirivimab + Imdevimab Emergency Use Authorization (EUA) Guidebook
NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab